Treatment of Rett Syndrome With Recombinant Human IGF-1
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01777542 |
Recruitment Status :
Completed
First Posted : January 29, 2013
Results First Posted : March 26, 2018
Last Update Posted : March 26, 2018
|
Sponsor:
Boston Children's Hospital
Collaborator:
International Rett Syndrome Foundation
Information provided by (Responsible Party):
Mustafa Sahin, Harvard Medical School (HMS and HSDM)
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Triple (Participant, Care Provider, Investigator); Primary Purpose: Treatment |
Condition |
Rett Syndrome |
Interventions |
Drug: Recombinant Human Insulin Growth Factor 1 (rhIGF-1) Drug: Placebo |
Enrollment | 30 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Assessments findings during the Screening Visit that could result in ineligibility after informed consent include:
|
Arm/Group Title | Placebo First, Then rhIGF-1 | rhIGF-1 First, Then Placebo |
---|---|---|
Arm/Group Description | One half of subjects will be randomly assigned to receive placebo during the first arm of the study. Subjects assigned to this group will receive twice daily subcutaneous injections of a saline solution (placebo). | One half of subjects will be randomly assigned to receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1) during the first arm of the study. Subjects assigned to this group will receive twice daily subcutaneous injections of IGF-1. |
Period Title: First Intervention (20 Weeks) | ||
Started | 15 | 15 |
Completed | 15 | 15 |
Not Completed | 0 | 0 |
Period Title: Washout Period (28 +/- 2 Weeks) | ||
Started | 15 | 15 |
Completed | 15 | 15 |
Not Completed | 0 | 0 |
Period Title: Second Intervention (20 Weeks) | ||
Started | 15 | 15 |
Completed | 15 | 14 |
Not Completed | 0 | 1 |
Reason Not Completed | ||
Adverse Event | 0 | 1 |
Baseline Characteristics
Arm/Group Title | All Participants | |
---|---|---|
Arm/Group Description | All 30 subjects enrolled and randomized in the study | |
Overall Number of Baseline Participants | 30 | |
Baseline Analysis Population Description |
[Not Specified]
|
|
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 30 participants | |
<=18 years |
30 100.0%
|
|
Between 18 and 65 years |
0 0.0%
|
|
>=65 years |
0 0.0%
|
|
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 30 participants | |
Female |
30 100.0%
|
|
Male |
0 0.0%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 30 participants | |
Hispanic or Latino |
26 86.7%
|
|
Not Hispanic or Latino |
3 10.0%
|
|
Unknown or Not Reported |
1 3.3%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Dr. Mustafa Sahin, Director of Translational Neuroscience Center |
Organization: | Boston Children's Hospital |
Phone: | 617-919-6258 |
EMail: | ResearchTNC@childrens.harvard.edu |
Publications:
Responsible Party: | Mustafa Sahin, Harvard Medical School (HMS and HSDM) |
ClinicalTrials.gov Identifier: | NCT01777542 |
Other Study ID Numbers: |
IRB-P00005610 |
First Submitted: | January 23, 2013 |
First Posted: | January 29, 2013 |
Results First Submitted: | November 20, 2017 |
Results First Posted: | March 26, 2018 |
Last Update Posted: | March 26, 2018 |